Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Sarepta Therapeutics Inc (SRPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sarepta's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
127.39 +3.14    +2.53%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
124.26
-3.13
-2.46%
0:51:07 - Real-time Data
  • Volume: 1,490,204
  • Bid/Ask: 125.50 / 129.50
  • Day's Range: 121.91 - 130.61
Type:  Equity
Market:  United States
Sarepta 127.39 +3.14 +2.53%

Sarepta Company Profile

 
Read the Sarepta company profile to learn more about the business and the management team. View Sarepta Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1162

Equity Type

ORD

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 215 First Street Suite 415
Cambridge, 02142
United States
Phone 617 274 4000
Fax -

Top Executives

Name Age Since Title
Douglas S. Ingram 58 2017 President, CEO & Director
M. Kathleen Behrens 69 2009 Independent Chairwoman
Beverly L. Davidson - 2015 Member of Strategic & Scientific Advisory Board
Hans Wigzell 83 2010 Chairman of Corporate Strategy Board & Independent Non-Employee Director
Louis M. Kunkel - 2015 Member of Strategic & Scientific Advisory Board
Kenneth H. Fischbeck - 2017 Member of Strategic & Scientific Advisory Board
Matthew Wood - 2017 Member of Strategic & Scientific Advisory Board
Steven Gray - 2019 Member of Scientific Advisory Board
Angela J. Russell - 2020 Member of Scientific Advisory Board
Carsten Bonnemann - 2019 Member of Scientific Advisory Board
Kay Davies - 2019 Member of Scientific Advisory Board
Annemieke Aartsma-Rus - 2019 Member of Scientific Advisory Board
Joy A. Cavagnaro - 2019 Member of Scientific Advisory Board
Stephen L. Mayo 60 2021 Independent Director
Michael Chambers 48 2022 Independent Director
Kathryn J. Boor 64 2022 Independent Director
Claude Nicaise 70 2015 Independent Non-Employee Director
Richard Jon Barry 64 2015 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SRPT Price Commentary

Write your thoughts about Sarepta Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ken Laing
Ken Laing Mar 31, 2021 7:46
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great opportunity to add, its just market rotation that has made it too low
Smooth Operator
Smooth_Operator Mar 01, 2021 14:18
Saved. See Saved Items.
This comment has already been saved in your Saved Items
overhyped company that has never delivered on their mandate. Price target 40
Simone Canalicchio
Simone Canalicchio Feb 26, 2021 23:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why this sadness although the vaccine?
Ken Laing
Ken Laing Jan 25, 2021 17:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Back to 170 within 6 months. Over 200 by end of the year.
Anfangell Anfangell
Anfangell Anfangell Jan 11, 2021 12:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Huge opportunity now to buy this Stock!!...I am in
Ahzam Ali
Ahzam Ali Jan 11, 2021 12:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How high will it go?
Anfangell Anfangell
Anfangell Anfangell Jan 11, 2021 12:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
As you can see now...And just beginning of rebound ;)
Leon Li
Leon Li Jan 08, 2021 18:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why has this stock dropped 50% today??
Shen Jie
Shen Jie Jan 08, 2021 18:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Because people mispret a research report , and solely on just one of their studies .
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email